GURUFOCUS.COM » STOCK LIST » USA » NYSE » Pfizer Inc (NYSE:PFE) » Definitions » Piotroski F-Score
Switch to:

Pfizer Piotroski F-Score

: 7 (As of Today)
View and export this data going back to 1951. Start your Free Trial

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pfizer has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Pfizer's Piotroski F-Score or its related term are showing as below:

PFE' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 6   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of Pfizer was 8. The lowest was 1. And the median was 6.


Pfizer Piotroski F-Score Historical Data

The historical data trend for Pfizer's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 5.00 6.00 5.00 7.00

Pfizer Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 6.00 7.00 6.00 7.00

Competitive Comparison

For the Drug Manufacturers - General subindustry, Pfizer's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Pfizer Piotroski F-Score Distribution

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Pfizer's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun22) TTM:Last Year (Jun21) TTM:
Net Income was 8146 + 3393 + 7864 + 9906 = $29,309 Mil.
Cash Flow from Operations was 10829 + 5914 + 6541 + 8170 = $31,454 Mil.
Revenue was 24094 + 23635 + 25661 + 27742 = $101,132 Mil.
Gross Profit was 14121 + 14046 + 15677 + 19094 = $62,938 Mil.
Average Total Assets from the begining of this year (Jun21)
to the end of this year (Jun22) was
(169920 + 179188 + 181476 + 183841 + 195290) / 5 = $181943 Mil.
Total Assets at the begining of this year (Jun21) was $169,920 Mil.
Long-Term Debt & Capital Lease Obligation was $34,294 Mil.
Total Current Assets was $67,466 Mil.
Total Current Liabilities was $47,410 Mil.
Net Income was 1469 + 846 + 4877 + 5563 = $12,755 Mil.

Revenue was 10277 + 11427 + 14516 + 18899 = $55,119 Mil.
Gross Profit was 8270 + 8716 + 10359 + 11903 = $39,248 Mil.
Average Total Assets from the begining of last year (Jun20)
to the end of last year (Jun21) was
(177934 + 178983 + 154229 + 158818 + 169920) / 5 = $167976.8 Mil.
Total Assets at the begining of last year (Jun20) was $177,934 Mil.
Long-Term Debt & Capital Lease Obligation was $35,354 Mil.
Total Current Assets was $48,814 Mil.
Total Current Liabilities was $35,664 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pfizer's current Net Income (TTM) was 29,309. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pfizer's current Cash Flow from Operations (TTM) was 31,454. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun21)
=29309/169920
=0.17248705

ROA (Last Year)=Net Income/Total Assets (Jun20)
=12755/177934
=0.07168388

Pfizer's return on assets of this year was 0.17248705. Pfizer's return on assets of last year was 0.07168388. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Pfizer's current Net Income (TTM) was 29,309. Pfizer's current Cash Flow from Operations (TTM) was 31,454. ==> 31,454 > 29,309 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun21 to Jun22
=34294/181943
=0.1884876

Gearing (Last Year: Jun21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun20 to Jun21
=35354/167976.8
=0.21046954

Pfizer's gearing of this year was 0.1884876. Pfizer's gearing of last year was 0.21046954. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun22)=Total Current Assets/Total Current Liabilities
=67466/47410
=1.42303312

Current Ratio (Last Year: Jun21)=Total Current Assets/Total Current Liabilities
=48814/35664
=1.36871916

Pfizer's current ratio of this year was 1.42303312. Pfizer's current ratio of last year was 1.36871916. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Pfizer's number of shares in issue this year was 5712. Pfizer's number of shares in issue last year was 5678. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=62938/101132
=0.62233517

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=39248/55119
=0.71205936

Pfizer's gross margin of this year was 0.62233517. Pfizer's gross margin of last year was 0.71205936. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun21)
=101132/169920
=0.5951742

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun20)
=55119/177934
=0.30977216

Pfizer's asset turnover of this year was 0.5951742. Pfizer's asset turnover of last year was 0.30977216. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+0+0+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pfizer has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Pfizer  (NYSE:PFE) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Pfizer Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Pfizer's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Pfizer Business Description

Pfizer logo
Address
235 East 42nd Street, New York, NY, USA, 10017
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
Executives
Denton David M officer: Chief Financial Officer & EVP 1000 LOWE'S BOULEVARD MOORESVILLE NC 28117
Pao William officer: Executive Vice President C/O CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017
Mcdermott Michael officer: Executive Vice President C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET 235 EAST 42ND STREET NY 10017
Malik Aamir officer: Executive Vice President C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017
Carapezzi William R Jr officer: Executive Vice President 600 MOUNTAIN AVENUE MURRAY HILL NJ 07921
Sahni Payal officer: Executive Vice President ATTN: PFIZER CORP. SECRETARY 235 EAST 42ND ST. NEW YORK NY 10017
Desmond-hellmann Susan director 513 PARNASSUS AVENUE S126 SAN FRANCISCO CA 94143
Hockfield Susan director GENERAL ELECTRIC COMPANY 41 FARNSWORTH STREET BOSTON MA 02210
Damico Jennifer B. officer: SVP & Controller C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017
Quincey James director THE COCA-COLA COMPANY ONE COCA-COLA PLAZA ATLANTA GA 30313
Gottlieb Scott director MOLECULAR INSIGHT PHARMACEUTICALS 160 SECOND STREET CAMBRIDGE MA 02142
Fonseca Lidia officer: Executive Vice President 358 SOUTH MAIN STREET BURLINGTON NC 27215
Goettler Michael officer: Group President 1000 MYLAN BOULEVARD CANONSBURG PA 15317
Rogers Dawn officer: Executive Vice President 235 EAST 42ND STREET NEW YORK NY 10017
Littman Dan R. director ATTN: CORPORATE SECRETARY PFIZER INC. 235 E. 42ND ST NEW YORK NY 10017

Pfizer Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)